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Cytokines play essential roles in the control of 
immune systems; they not only act as growth 
factors but also regulate the diff  erentiation, 
maintenance, and activation of naive, eff  ector, 
and memory state of immune cells. Their cyto-
plasmic signal transduction pathways are well 
defi  ned. Upon binding of cytokines to their re-
ceptors and subsequent receptor dimerization, 
receptor-associated JAKs become activated and 
phosphorylate tyrosine residues in the cytoplas-
mic domains of receptors, which serve as the 
binding sites for Src homology 2 (SH2) domain 
of STAT molecules. After phosphorylation of 
STATs by JAKs, STATs dimerize and translo-
cate into the nucleus to induce transcription of 
cytokine-  responsive genes (1, 2).
The cytokine milieu and their intracellular 
signaling molecules are also involved in naive 
CD4+ Th diff  erentiation. It is well established 
that IL-12/STAT4 and IL-4/STAT6 are nec-
essary for Th1 and Th2 diff  erentiation, respec-
tively. In addition, IFN-γ–STAT1 pathway is 
also necessary for Th1 diff   erentiation (3, 4). 
The molecular mechanism for generating Th3 
regulatory cells, which is a unique Th cell sub-
set that primarily secretes TGF-β1, is poorly 
understood. TGF-β1 secreted from Th3 cells 
provides help for IgA induction and has sup-
pressive properties for both Th1 and Th2 cells 
(5, 6). Because TGF-β1 KO mice exhibited se-
vere multiorgan infl  ammations (7, 8), TGF-β1 
has been thought to be an important immune 
regulatory cytokine. TGF-β1 is also suggested 
to be involved in the regulatory function of 
CD4+ CD25+ regulatory T cells (9, 10), though 
the molecular mechanism of TGF-β1 induc-
tion in such regulatory-type T cells remains to 
be elucidated. Because production of TGF-β1 
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Suppressor of cytokine signaling (SOCS)3 is a major negative feedback regulator of signal 
transducer and activator of transcription (STAT)3-activating cytokines. Transgenic mouse 
studies indicate that high levels of SOCS3 in T cells result in type 2 T helper cell (Th2) 
skewing and lead to hypersensitivity to allergic diseases. To defi  ne the physiological roles of 
SOCS3 in T cells, we generated T cell–specifi  c SOCS3 conditional knockout mice. We found 
that the mice lacking SOCS3 in T cells showed reduced immune responses not only to 
ovalbumin-induced airway hyperresponsiveness but also to Leishmania major infection. 
In vitro, SOCS3-defi  cient CD4+ T cells produced more transforming growth factor (TGF)-𝗃1 
and interleukin (IL)-10, but less IL-4 than control T cells, suggesting preferential Th3-like 
differentiation. We found that STAT3 positively regulates TGF-𝗃1 promoter activity de-
pending on the potential STAT3 binding sites. Furthermore, chromatin immunoprecipitation 
assay revealed that more STAT3 was recruited to the TGF-𝗃1 promoter in SOCS3-defi  cient 
T cells than in control T cells. The activated STAT3 enhanced TGF-𝗃1 and IL-10 expression 
in T cells, whereas the dominant-negative form of STAT3 suppressed these. From these 
fi  ndings, we propose that SOCS3 regulates the production of the immunoregulatory cyto-
kines TGF-𝗃1 and IL-10 through modulating STAT3 activation.
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is greatly enhanced by IL-4 and IL-10 in Th cells, while sup-
pressed by IFN-γ (11), cytokine signals may play critical roles 
in the induction and regulation of TGF-β1 production.
In the physiologic condition as well as in pathological 
conditions, functions of cytokines are strictly controlled. Cy-
tokine signaling pathways are negatively regulated by the 
family of proteins called suppressors of cytokine signaling 
(SOCSs), which are characterized by the presence of an SH2 
domain and a COOH terminal conserved domain termed 
the SOCS-box. Several reports have indicated that SOCS 
proteins are necessary for regulation of normal immune re-
sponses (12). Among them, SOCS3, which associates with 
the tyrosine kinase Lck, calcineurin, and CD28, has been 
shown to inhibit IL-2 production during T cell activation 
(13–16). During Th diff  erentiation, SOCS3 is selectively ex-
pressed in Th2 cells, whereas SOCS1 expression is higher in 
Th1 than in Th2 cells (17, 18). In the analysis of Lck pro-
moter-driven SOCS3-transgenic mice, the high expression 
of SOCS3 in Th cells led to skewing to Th2-type diff  erentia-
tion. This is probably because SOCS3 binds to IL-12Rβ2 
and inhibits IL-12–mediated STAT4 activation, thereby 
blocking Th1 development (18, 19). Importantly, SOCS3 
levels were high in T cells from allergic disease patients (18). 
These observations implied that SOCS3 might be crucial for 
Th cell diff  erentiation and activation. However, as most of 
these conclusions have been drawn by overexpression studies 
or in pathological conditions such as asthma and atopy, analy-
sis of SOCS3-defi  cient mice has been necessary to clarify the 
physiological function of SOCS3 in T cells more precisely. 
Because mice lacking SOCS3 die during embryogenesis as 
the result of a placental defect by an enhanced activation of 
the leukemia inhibitory factor (LIF) signaling pathway (20, 
21), we generated T cell–specifi  c SOCS3-defi  cient (condi-
tional KO [cKO]) mice by a conditional gene targeting ap-
proach using Cre-loxP system (22). We showed that not only 
Th2-type responses in OVA-induced asthma model but also 
immune responses against Leishmania major infection were re-
duced in cKO mice. In vitro analysis of T cells demonstrated 
that SOCS3-defi  cient CD4+ T cells produced more TGF-
β1 and IL-10, but less IL-4 than WT T cells, suggesting a 
preferential Th3-like diff  erentiation. We found that STAT3 
bound to the TGF-β1 promoter and elevated the promoter 
activity, and SOCS3 deletion enhanced STAT3 recruitment 
to the promoter. It has been shown that STAT3 also binds to 
the IL-10 promoter and elevates IL-10 gene expression (23). 
In conclusion, we propose that STAT3 and SOCS3 recipro-
cally regulate Th cell function and diff  erentiation by control-
ling the induction of the immunosuppressive cytokine, 
TGF-β1, and IL-10.
RESULTS
Generation of T cell–specifi  c SOCS3-defi  cient mice
To delete the SOCS3 gene in a T cell–specifi  c  manner, 
proximal p56Lck promoter-cre transgenic mice were crossed 
with SOCS3-fl  ox/fl   ox mice (22) (Fig. 1 A). Resulting 
SOCS3-fl  ox/fl  ox: Lck-cre Tg mice are designated as cKO 
mice. SOCS3 WT alleles, fl  oxed alleles, and the Lck-cre trans-
gene were determined by PCR using genomic DNA from 
tails and CD4+ T cells. A 380-bp product corresponding to 
the nondeleted fl  oxed alleles was amplifi  ed by primer set of a 
and b from tail DNA of SOCS3-cKO and WT-fl  ox/fl  ox 
mice (C57BL/6 showed a 280-bp fragment because of the 
lack of fl  oxed alleles). An approximately 1.2-kbp fragment 
was amplifi  ed from DNA isolated from CD4+ T cells of 
WT-fl  ox/fl  ox mice by the primer set of a and c, whereas a 
250-bp fragment corresponding to the deleted allele was am-
plifi  ed from SOCS3-cKO mice CD4+ T cells (Fig. 1 B). 
Deletion of the SOCS3-fl  ox gene was specifi  c to T cells, and 
no deletion was observed in B cells and DCs in cKO mice 
(Fig. 1 C). Next, to confi  rm the deletion of mRNA, we per-
formed RT-PCR analysis in IL-6–stimulated splenic CD4+ 
T cells from SOCS3-cKO mice. Although SOCS3 was 
Figure 1.  Generation of T cell–specifi  c SOCS3-defi  cient mice. 
(A) Schema of SOCS3 fl  oxed and deleted loci. Exon 2 was fl  anked by two 
LoxP sites (arrowheads). (B) PCR genotyping of fl  oxed alleles using the 
primer set of a and b against tail genome and deleted alleles using the 
primer set of a and c against genomic DNA of CD4+ T cells from indicated 
mice. (C) PCR detection of undeleted and deleted fl  oxed alleles using 
primer set a and c against genomic DNA from B cells, DCs, and CD4+ 
T cells. (D) RT-PCR analysis for mRNA expression of SOCS3, IL-6R, and 
  glyceraldehydes-3-phoshate dehydrogenase (G3PDH) in IL-6–stimulated 
MACS purifi  ed splenic CD4+ T cells from cKO and WT mice. (E) Western 
blotting analysis for SOCS3 and phosphorylated STAT3 in splenic CD4+ T cells.JEM VOL. 203, April 17, 2006  1023
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  induced after IL-6 stimulation in WT CD4+ T cells and the 
expression of IL-6 receptor was at an almost equal level, 
SOCS3 mRNA was undetectable in CD4+ T cells from 
SOCS3-cKO mice (Fig. 1 D). Western blotting analysis us-
ing antibody specifi  c for SOCS3 also confi  rmed the absence 
of SOCS3 protein in CD4+ T cells from SOCS3-cKO mice 
(Fig. 1 E). Thus, we concluded that cre-mediated deletion of 
SOCS3 occurred effi   ciently  and  specifi   cally in T cells in 
SOCS3-cKO mice.
We examined IL-6–mediated STAT3 activation in 
SOCS3-defi  cient T cells. As shown in Fig. 1 E, IL-6–induced 
STAT3 activation was enhanced and prolonged in SOCS3-
defi  cient CD4+ T cells. This confi  rmed a negative regulatory 
function of SOCS3 for the gp130–STAT3 pathway. As in 
macrophages (22), SOCS3 defi  ciency in T cells did not much 
aff  ect IL-10–induced STAT3 activation (unpublished data).
Next, we examined development of T cells in SOCS3 
cKO mice. Total mononuclear cell numbers of lymphoid or-
gans such as thymus, spleen, and lymph nodes in SOCS3-cKO 
mice were almost the same as those in WT mice. Flow cyto-
metric analysis revealed that the ratio of CD4+ or CD8+ SP 
cells was not altered in SOCS3 cKO mice,   although the num-
bers of CD4− CD8− DN cells were slightly higher in SOCS3-
cKO mice (unpublished data). T cell numbers, the CD4/CD8 
Figure 2.  Reduced Th2 responses of SOCS3-defi  cient T cells in 
OVA/alum immunized mice. (A) Analyses of serum OVA-specifi  c IgG1, 
IgG2a, and IgE titers in cKO and WT mice. Plasma samples were taken from 
mice (n = 5) at indicated days after immunization with OVA/alum on days 
0 and 14. Ab titers were measured by ELISA and endpoint analysis. Data 
indicate mean ± SD. (B) Mice (n = 9 for each group) immunized with 
OVA/alum were aerosol challenged with OVA. Airway responsiveness was 
determined by the acetylcholine-dependent change in airway pressure in 
saline-treated control and OVA-sensitized/challenged WT and SOCS3-cKO 
mice. Provocative concentration 200 (PC200), the concentration 
at which airway pressure is 200% of its baseline value. Data indicate 
mean ± SD. (C) Cell counts in bronchoalveolar lavage fl  uid. *, P < 0.05 by 
analysis of variance with Bonferroni correction. Data indicate mean ± SD. 
(D) Cytokine profi  les of Th1 type (IFN-γ), Th2 type (IL-4 and IL-5), and 
TGF-β1 and IL-10. Splenic CD4+ T cells isolated from OVA-immunized mice 
were restimulated with or without OVA ex vivo for 48 h. Cytokine levels 
were determined by ELISA. Data indicate mean ± SD in one representative 
experiment with fi  ve mice per group out of three independent experiments.1024  SOCS3 REGULATES IL-10 AND TGF-β1 PRODUCTION | Kinjyo et al.
ratio, and other T cell markers (TCRβ, CD25, CD69, 
CD62L) were not altered in the spleen and lymph node of 
cKO mice (unpublished data). Therefore, we concluded that 
SOCS3 does not play an   essential role in T cell development.
Reduced Th2-type response in SOCS3-cKO mice
Previously, we reported that constitutive expression of SOCS3 
in T cells causes preferential Th2 diff  erentiation of CD4+ T 
cells, resulting in hyper IgE production and enhanced OVA-
induced airway hypersensitiveness (18). Thus, we investigated 
the eff  ect of SOCS3 deletion in T cells on OVA immuniza-
tion. After mice were immunized with OVA and alum as an 
adjuvant on days 1 and 14, we examined the Ig levels and 
  cytokine production. Total IgG1 and IgG2a levels before 
  immunization were almost the same between WT and cKO 
mice (unpublished data). As shown previously (24), OVA/
alum immunization signifi  cantly enhanced Th2-mediated Ig 
(IgG1 and IgE) production (Fig. 2 A). Interestingly, SOCS3-
cKO mice produced lower levels of IgG1 and IgE than WT 
mice did, although Th1-mediated IgG2a production was sim-
ilarly low between WT and cKO mice (Fig. 2 A). Refl  ecting 
reduced IgE levels, SOCS3-cKO mice exhibited lower sensi-
tivity to airway responsiveness and reduced eosinophil infi  ltra-
tion in BAL fl  uids in cKO mice after OVA challenge compared 
with WT mice (Fig. 2, B and C). These data confi  rmed that 
SOCS3 levels in Th cells alter type 2 responses in vivo.
Next, cytokine production by OVA restimulation from 
splenic CD4+ T cells was examined. When CD4+ T cells 
from OVA/alum-immunized mice were restimulated with 
OVA in vitro, the Th2-type signature cytokines such as IL-4 
and IL-5 were highly produced, whereas in the Th1-type 
signature cytokine, IFN-γ levels were very low (Fig. 2 D). 
Levels of these Th2-type cytokines from CD4+ T cells were 
not signifi  cantly diff  erent between WT and SOCS3 cKO 
mice (Fig. 2 D). However, in several separate experiments, 
we always observed that T cells from cKO mice immunized 
with OVA/alum produced a slightly lower amount of IL-4 
than those from WT mice (Fig. 2 D). We did not observe 
enhanced IFN-γ production in T cells from SOCS3-cKO 
mice, suggesting that loss of SOCS3 in Th cells did not en-
force Th1 skewing. In contrast with Th2-type cytokines, 
TGF-β1 and IL-10 levels were higher in SOCS3-cKO mice 
than in WT mice (Fig. 2 D). We also confi  rmed high mRNA 
expression levels of TGF-β1 and IL-10 by RT-PCR (un-
published data). During in vitro restimulation, no signifi  cant 
diff  erence in the proliferation was observed between WT 
and SOCS3-defi  cient T cells (unpublished data). These re-
sults indicate that loss of SOCS3 expression in T cells resulted 
in lower Th2-type immune responses, which was accompa-
nied with reduced IL-4 levels; however, production of TGF-
β1 and IL-10, but not IFN-γ, was enhanced.
Altered immune responses to L. major infection 
in SOCS3-cKO mice
To further determine the role of SOCS3 in Th cell diff  erentia-
tion and function, we compared the immune responses against 
L. major, the intracellular protozoan parasite infection, the res-
olution of which is strictly dependent on Th1-type immune 
responses (25, 26). Because genetic background of both WT 
and cKO mice was 129 × C57BL/6 mixed, these mice are 
generally expected to be resistant to L. major compared with 
susceptible BALB/c mice. Mice were infected subcutaneously 
in the right hind footpad with 107 L. major promastigotes, and 
lesion development was monitored for 8 wk. Both WT and 
cKO mice were resistant to L. major, which was judged by 
footpad swelling (Fig. 3 A). However, the number of parasites 
remaining in the lesion at 6 wk after infection was higher in 
cKO mice than in WT mice (Fig. 3 B). Moreover, serum an-
tibody levels after L. major infection were lower in cKO mice 
than in WT mice after infection (Fig. 3 C), suggesting that im-
mune responses against L. major were reduced in cKO mice.
We examined cytokine production in CD4+ T cells from 
right popliteal LN at 4 wk after L. major infection (Fig. 3 D). 
After in vitro stimulation with L. major antigen, the IFN-γ 
level from SOCS3-defi  cient CD4+ T cells was comparable 
to that of WT CD4+ T cells, suggesting that eff  ective Th1 
diff  erentiation occurred in cKO mice. IL-4 levels were too 
low to compare between WT and cKO mice. Next, we 
measured IL-10 and TGF-β1 levels in the same supernatant. 
As shown in Fig. 3 D, enhanced production of IL-10 and 
TGF-β1 was observed in CD4+ T cells from SOCS3-cKO 
mice. Similar higher expression of IL-10 and TGF-β1 in the 
CD4+ T cells of SOCS3-cKO mice than in WT T cells was 
confi  rmed by RT-PCR (Fig. 3 E). These data support our 
notion that SOCS3-defi  cient T cells possess higher potential 
to produce IL-10 and TGF-β1 than WT T cells.
Cytokine production from in vitro–differentiated 
SOCS3-defi  cient T cells
To elucidate the reason why IL-10 and TGF-β1 were ele-
vated in CD4+ T cells from SOCS3-cKO mice, we analyzed 
in vitro Th cell diff  erentiation. Purifi  ed CD4+ T cells were 
stimulated under Th0, Th1, and Th2 skewing conditions for 
7 d and restimulated with plate-bound anti-CD3ε and anti-
CD28 antibodies. TCR-mediated tyrosine phosphorylation 
of cellular proteins and ERK activation in T cells were not 
signifi  cantly altered in cKO mice (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20052333/DC1). Fur-
thermore, there was no signifi  cant diff  erence in proliferation 
between WT and SOCS3-defi  cient CD4+ T cells after TCR 
stimulation (unpublished data). Neither IFN-γ nor IL-4 was 
detected in the culture supernatant of both SOCS3-defi  cient 
and WT T cells under Th0 conditions. Under Th1 diff  eren-
tiating condition, the IFN-γ level was slightly reduced in 
SOCS3-defi  cient T cells compared with WT T cells (Fig. 
4 A). In Th2 diff  erentiating condition, IL-4 from SOCS3-
defi  cient T cells was also signifi  cantly lower than that of WT 
T cells (Fig. 4 A). In contrast, IL-10 and TGF-β1 levels were 
higher in SOCS3-defi  cient CD4+ T cells than in WT CD4+ 
T cells (Fig. 4 B). In Th0 and Th1 conditions, IL-10 and 
TGF-β1 levels were very low in both WT and SOCS3-
  defi  cient T cells (Fig. 4 B and not depicted).JEM VOL. 203, April 17, 2006  1025
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We next examined Th3 diff  erentiation, which has been 
induced in vitro by culturing CD4+ T cells in the presence of 
IL-4, IL-10, and TGF-β1 (11, 27). As previously described, 
TGF-β1 levels were especially enhanced in the Th3 condi-
tion compared with the Th2 condition (Fig. 4 B). Under this 
Th3 condition, SOCS3-defi  cient CD4+ T cells produced 
higher levels of IL-10 and TGF-β1 than WT CD4+ T cells 
(Fig. 4 B). Collectively, SOCS3 defi  ciency caused enhanced 
production of TGF-β1 and IL-10, but reduced production 
of IL-4 in CD4+ T cells not only in vivo but also in vitro.
STAT3 elevates TGF-𝗃1 promoter activity
The inhibitory eff  ect of SOCS3 is relatively specifi  c to STAT3 
among six STATs. Therefore, we next investigated whether 
STAT3 could directly regulate the TGF-β1 promoter activ-
ity. The 4.1-kb fragment of the 5′-fl  anking region of the 
  murine TGF-β1 gene was fused to the luciferase expression 
vector, and promoter activity was examined in HEK293 cells 
by transient transfection. Luciferase gene expression was in-
duced not only by high glucose and TGF-β1 itself as de-
scribed previously (28) but also by LIF, suggesting that this 
4.1-kb 5′-fragment of the TGF-β1 gene contained STAT3 
responsive elements (Fig. 5 A). Co-expression of exogenous 
Figure 3.  Reduced Th1 responses of SOCS3-defi  cient T cells in 
L. major infection. (A) Footpad swelling after L. major infection. BALB/c 
(a susceptible strain), WT, and SOCS3-cKO mice were inoculated in the right 
hind footpad with L. major promastigotes and the size of the footpad lesion 
was monitored. Data shown are mean ± SD and are representative of three 
independent experiments. BALB/c mice were killed at 4 wk for ethical 
reasons. (B) The number of parasites remaining in the footpads 6 wk after 
infection. (C) Serum IgG1, IgG2a, and IgE levels against L. major antigen in 
infected mice. Samples were collected from WT (open squares) and cKO 
(closed squares) mice 4 wk after infection. Total IgG1, IgG2a, and IgE titers 
were determined by ELISA. (D) Cytokine production by CD4+ T cells of the 
right popliteal LN from WT and cKO mice 4 wk after L. major infection. CD4+ 
T cells were cultured with irradiated naive WT splenocytes with (black bar) or 
without (gray bar) L. major antigen for 70 h. Concentrations of IFN-γ, IL-4, 
IL-10, and TGF-β1 in the culture supernatant were measured by ELISA. Data 
indicate mean ± SD of triplicate samples from fi  ve mice per group in one 
representative experiment out of three independent experiments. (*, P < 
0.01). (E) IFN-γ, IL-10, and TGF-β1 mRNA levels determined by RT-PCR 
  using total RNA from CD4+ right popliteal LN 4 wk after L. major infection.
Figure 4.  Cytokine production from in vitro–differentiated CD4+ 
T cells. IFN-γ and IL-4 production from in vitro–differentiated Th0/Th1/
Th2 cells (A), and IL-10 and TGF-β1 production from Th0/Th2/Th3 cells (B). 
Naive CD4+ T cells were cultured under various differentiation conditions 
for 7 d as described in Materials and methods. After restimulation with 
anti-CD3ε mAb and anti-CD28 mAb for 24 h for IFN-γ, and with IL-4 and 
IL-10 for 72 h for TGF-β1, culture supernatants were collected and ana-
lyzed by ELISA. Data indicate mean ± SD of triplicate cultures in one rep-
resentative experiment out of three independent experiments. *, P < 0.01.1026  SOCS3 REGULATES IL-10 AND TGF-β1 PRODUCTION | Kinjyo et al.
WT STAT3 enhanced LIF-mediated TGF-β1 promoter ac-
tivity in a dose-dependent manner (Fig. 5 A). Furthermore, 
constitutive active form of STAT3 (STAT3c) (29) also en-
hanced TGF-β1 promoter activity similar to LIF stimulation 
(Fig. 5, A and B), suggesting that STAT3 positively regulates 
TGF-β1 promoter. We also confi  rmed that STAT3 elevated 
TGF-β1 promoter activity in the lymphoid cell line by using 
Jurkat cell (unpublished data).
As shown in Fig. 5 B, a reporter assay using a series of 
5′-deletion mutants revealed that the LIF-responsive elements 
were present upstream of −1755. By searching for potential 
STAT3-binding sites with the consensus sequences, TTC/
A(N)3G/TAA (30), two candidates of STAT3-binding sites 
were identifi  ed in the 4.1-kb TGF-β1 5′-fl  anking region. 
The two sites were at positions −3155 and −2515 upstream 
of the transcription initiation site in the TGF-β1 promoters 
designated STAT3-binding element (SBE)-1 and SBE-2, re-
spectively. To determine the signifi  cance of these elements, 
mutations were introduced into the SBE-1 and/or SBE-2 
sites. A mutant promoter lacking both SBE-1 and SBE-2 
did not respond to LIF stimulation anymore, whereas con-
structs containing a single SBE site still responded to STAT3 
(Fig. 5, B and C). These results indicate that the two SBE 
sites of the TGF-β1 promoter are important for STAT3-
dependent activation.
To confi  rm STAT3 binding to the TGF-β1 promoter in 
T cells, chromatin immunoprecipitation (ChIP) assay was 
performed (Fig. 5 D). The chromatin–DNA complex was 
immunoprecipitated with anti-STAT3 antibody; then, 
STAT3 binding to the TGF-β1 promoter was analyzed using 
pairs of specifi  c primers spanning the STAT3 binding sites. 
The SBE site of the c-fos promoter was used as a positive 
control of STAT3 recruitment (31). As shown in Fig. 5 D, 
STAT3 was actually bound to the TGF-β1 promoter region 
containing SBE-1 site in T cells in an IL-6–dependent man-
ner. These data indicate that TGF-β1 is a direct downstream 
target of STAT3.
STAT3 positively regulates TGF-𝗃1 and IL-10 induction 
in CD4+ T cells
To address whether STAT3 is critical for IL-10 and TGF-β1 
production in CD4+ T cells, we introduced a constitutive 
active form of STAT3 (STAT3c) or a dominant negative 
STAT3 (dNSTAT3) (32) into CD4+ T cells using a bicis-
tronic retroviral vector pMX carrying IRES-GFP (33) (Fig. 
6 A). The retrovirus vectors were infected into nonpolar-
ized CD4+ T cells, which were stimulated with plate-bound 
anti-CD3ε mAb and anti-CD28 mAb, and on day 4, GFP-
positive cells were sorted. The expression of myc-STAT3 
in the sorted GFP-positive CD4+ T cells was confi  rmed by 
Western blotting (Fig. 6 B). These cells were cultured under 
Th0 or Th3 diff  erentiating condition for 7 d and analyzed 
for cytokine production upon restimulation. We found 
that introduction of STAT3c into CD4+ T cells resulted in 
higher TGF-β1 and IL-10 production (Fig. 6 C). In con-
trast, dNSTAT3-GFP introduced to CD4+ T cells showed 
less production of TGF-β1 and IL-10 (Fig. 6 C). These data 
indicate that STAT3 activation is positively involved in the 
production of TGF-β1 and IL-10 in CD4+ T cells.
Next, STAT3 recruitment to the TGF-β1 promoter was 
compared between WT and SOCS3-defi  cient CD4+ T cells 
using the ChIP assay. As shown in Fig. 6 D, STAT3 was 
  recruited to the TGF-β1 promoter region under the Th3, 
but not Th0, diff  erentiating conditions. Importantly, more 
STAT3 was recruited to the TGF-β1 promoter in SOCS3-
defi  cient CD4+ T cells than in WT CD4+ T cells under the 
Th3 diff  erentiating condition. These data suggest that SOCS3 
probably regulates the production of TGF-β1 through ap-
propriate tuning of STAT3 activation in CD4+ T cells.
D  I  S  C  U  S  S  I  O  N 
Previously, we reported that forced expression of SOCS3 in 
T cells resulted in Th2 skewing. SOCS3 expression levels are 
high in T cells from patients with asthma and atopy. There-
fore, we concluded that high SOCS3 levels are related to 
pathological conditions, especially Th2-type diseases (18). 
However, the role of SOCS3 in physiological conditions 
has not been clarifi  ed. Here, we generated T cell–specifi  c 
SOCS3-cKO mice and found that the Th2 immune re-
sponses in SOCS3-cKO mice were actually reduced. How-
ever, this is not the result of higher Th1 responses. Our 
SOCS3-defi  cient CD4+ T cells showed higher TGF-β1 and 
IL-10 production compared with control WT CD4+ T cells. 
Thus, we suspect that reduced Th2 responses in SOCS3-
cKO mice may be the result of immunosuppression by these 
two immunoregulatory cytokines.
We proposed that SOCS3 inhibits Th1 diff  erentiation by 
suppressing IL-12–mediated signaling (18). We found that 
IL-12–induced STAT4 phosphorylation was actually en-
hanced in SOCS3-defi   cient T cells compared with WT 
T cells (unpublished data). However, similar or only slightly 
reduced IFN-γ production occurred in CD4+ T cells from 
SOCS3 cKO mice compared with WT mice (Figs. 3 D and 
4 A). Furthermore, delay of parasite clearance and reduced 
production of antibodies were observed in cKO mice during 
L. major infection (Fig. 3, B and C). This may be the result of 
immunosuppressive eff  ect of TGF-β1 and IL-10 produced 
from T cells during infection. Regulatory roles of SOCS3-
defi  cient T cells in other immune reactions should be defi  ned 
in future studies.
Recently, regulatory functions of Th cells have been ex-
tensively studied. CD4+ CD25+ regulatory T (T reg) cells 
are recognized as naturally occurring T reg cells and exhibit 
immunosuppressive abilities by a mechanism that is depen-
dent on cell-to-cell contact through the interaction of 
CTLA-4 with CD86 (34). Though TGF-β1 is shown to be 
one of the mechanisms of the immunosuppressive eff  ects of 
T reg cells (10) and Foxp3 has been shown to be an essential 
transcription factor in the generation and function of T reg 
cells (35), we did not fi  nd any change in the number of CD4+ 
CD25+ T reg population or Foxp3 expression between 
SOCS3-defi   cient and WT T cells (unpublished data). JEM VOL. 203, April 17, 2006  1027
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  However, regulatory function of SOCS3-defi   cient T reg 
cells remains to be investigated.
Previous studies have identifi  ed another subset of T reg 
cells; Tr1 cells (T reg cell 1), which are induced in vitro by 
repeated antigen stimulation of T cells in the presence of IL-
10 (36, 37). Tr1 cells produce high levels of IL-10 rather than 
TGF-β1 (38). The additional subset of T reg cells is Th3, 
which is induced by orally administered antigens. Th3 cells 
Figure 5.  STAT3 directly enhances TGF-𝗃1 promoter activity. 
(A) HEK293 cells were transfected with 0.2 μg of pTGF4.1-luc, a reporter 
gene containing  4.1 kb TGF-β1 promoter region, and 0.1 μg of β-
  galactosidase expression vector (β-gal) together with 0, 0.2, 0.6 μg WT-
STAT3 or STAT3c expression vector. 1 d after transfection, cells were 
stimulated with 10 ng/ml LIF or 10 ng/ml TGF-β1 and luciferase activity 
was measured after 8 h. Luciferase activities were normalized by β-gal 
activities and expressed as fold induction to control cultures defi  ned as 
1.0. STAT3 expression levels determined by Western blotting analysis as 
shown (bottom). (B) Localization of the STAT3 responsive elements in the 
TGF-β1 promoter. HEK293 cells were transiently transfected with 0.2 μg 
of plasmid containing various fragments of TGF-β1 promoter region and 
0.1 μg of β-gal expression vector. 1 d after transfection, cells were 
  stimulated with 10 ng/ml LIF or 10 ng/ml TGF-β1 for 8 h and harvested. 
(C) Effects of point mutations introduced into the SBE-1 and SBE-2 
  elements. HEK293 cells were transiently transfected with WT or mutant 
pTGF4.1-luc plasmids and β-gal plasmid. Cells were stimulated with 
10 ng/ml LIF and luciferase activities were measured. Luciferase activities 
were normalized by β-gal activities and expressed as fold induction to 
control cultures defi  ned as 1.0. (D) ChIP assay was performed using chro-
matin from WT CD4+ T cells treated with IL-6 for 3 h and immunopre-
cipitated with antibody against STAT3. The fi  nal DNA extractions were 
amplifi  ed using pairs of primers that cover the STAT3 binding site (SBE-1) 
in the TGF-β1 or c-fos promoter region. G3PDH levels were determined 
by PCR using samples before immunoprecipitation as input control. 
  Luciferase activities normalized by β-gal activity are shown as the 
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can be distinguished from Th2 cells by cytokine profi  les; Th3 
cells produce much more TGF-β1 and IL-10 and less IL-4 
than Th2 cells (11, 39). Because SOCS3-defi  cient CD4+ T 
cells produce more TGF-β1 and IL-10, they are more likely 
to exhibit a Th3-like phenotype.
In this study, we demonstrated that STAT3 directly binds 
to the promoter region of TGF-β1 and elevates TGF-β1 
production in T cells. It has already been shown that IL-10 is 
up-regulated by STAT3 (23). We showed that constitutive 
active form of STAT3 enhanced TGF-β1 and IL-10 produc-
tion in T cells. Furthermore, we showed that a dominant 
negative STAT3 suppressed TGF-β1 production (Fig. 6 C). 
Therefore, STAT3 could be a positive regulator of Th3-type 
diff   erentiation. STAT3 being required for Th3 is unlike 
STAT4 and STAT6 being required for Th1 and Th2, respec-
tively, because basal transcription of TGF-β1 and IL-10 is 
not completely dependent on STAT3. However, STAT3 is 
an important regulatory factor for Th3 diff  erentiation because 
STAT3 is essential for the immunosuppressive function of 
IL-10 in macrophages (40) and IL-10 is usually necessary for 
induction of Th3 in vitro. Collectively, STAT3 seems to 
positively regulate induction and/or diff  erentiation of Th3.
A question that remains unsolved is what kind of cyto-
kines are regulated by SOCS3 during Th3-like phenotype 
induction. Previously, IL-4 has been shown to induce SOCS3 
expression in Th2 cells (17). However, IL-4–induced STAT6 
phosphorylation levels were not aff  ected in SOCS3-defi  cient 
T cells (unpublished data). Therefore, it is unlikely that 
SOCS3 directly regulates IL-4 signaling. Because STAT3 is 
strongly activated by IL-10, we compared IL-10–induced 
STAT3 activation between WT and SOCS3-defi  cient T cells. 
In SOCS3-defi   cient T cells, however, IL-10–mediated 
STAT3 activation was not much aff  ected (unpublished data). 
This is probably because SOCS3 does not bind to the IL-10 
receptor (22). In contrast, we observed stronger and pro-
longed STAT3 activation in response to IL-6 and IL-27 in 
SOCS3-defi   cient T cells (Fig. 1 E and not depicted). 
  Furthermore, STAT3 recruitment to the TGF-β1 promoter 
under Th3 diff  erentiation condition was enhanced in SOCS3-
defi  cient CD4+ T cells. Although we could not conclude 
that IL-6 is responsible for the Th3-like phenotype of 
SOCS3-defi  cient  CD4+ T cells, these results suggest that 
STAT3 is hyperactivated in SOCS3-defi  cient T cells during 
T cell diff  erentiation, and this is the result of the hypersensi-
tivity to autocrine or paracrine cytokines that activate STAT3. 
Identifi   cation of these cytokines other than IL-10, which 
modulate TGF-β1 and IL-10 production, will be important 
for understanding of the regulation of Th3 diff  erentiation.
Another possibility for answering the unsolved question 
is that SOCS3 aff  ects TCR signaling. SOCS3 has been shown 
to be able to interact with tyrosine kinase Lck, calcineurin, 
and CD28 (13–16). The level of SOCS3 expression is signifi  -
cantly high in resting CD4+ T cells and rapidly decreased af-
ter TCR stimulation (unpublished data). Some reports have 
shown that the strength of TCR stimulation is an important 
factor for Th diff  erentiation. Although we could not detect 
apparent diff  erences in proliferation, tyrosine phosphoryla-
tion of cellular proteins, and ERK activation between 
SOCS3-defi  cient and WT T cells in response to TCR stimu-
lation (Fig. S1 and not depicted), the absence of SOCS3 in 
naive CD4+ T cells may permit some stronger TCR signal-
ings, which might lead to higher IL-10 and TGF-β1 secre-
tion at an early stage of T cell activation, thereby leading to 
large diff  erences at later stages of T cell diff  erentiation.
Although the more detailed molecular basis of the hyper-
production of TGF-β1 and IL-10 in SOCS3-defi  cient  T 
cells has remained elusive, our biochemical analyses suggest 
Figure 6.  Retroviral transduction of STAT3 mutants modulates 
TGF-𝗃1 and IL-10 production. (A) Schematic structure of the retroviral 
pMX vectors containing mutant STAT3, either myc-STAT3c (constitutive 
active form) or myc-dNSTAT3 (dominant negative form). (B) GFP-positive 
cells were sorted from infected T cells and the expression levels of exoge-
neous myc-STAT3 were examined by Western blotting. (C) IL-10 and 
TGFβ1 production from infected CD4+ T cells after Th3 differentiation. 
GFP-positive cells were cultured in the presence of IL-4, IL-10, and TGF-
β1 for 7 d and restimulated with anti-CD3ε mAb and anti-CD28 mAb and 
cytokines in the culture supernatants were measured by ELISA. Data 
shown are mean ± SD of triplicate samples from four independent exper-
iments. (D) ChIP assay to compare STAT3 recruitment to TGF-β1 promoter 
(SBE-1 site) between Th0 and Th3 differentiated T cells from WT and cKO 
mice. Anti-STAT3 Ab immunoprecipitates were used as templates for PCR 
cells. A non-SBE region near the transcription initiation sites was ampli-
fi  ed as a negative control. Ratios of the bands intensity of SBE-1 PCR 
products and those of control (G3PDH) in two independent experiments 
are plotted (right).JEM VOL. 203, April 17, 2006  1029
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that SOCS3 regulates TGF-β1 and IL-10 production by 
  suppressing STAT3 activity. Thus, we propose that STAT3 
and SOCS3 reciprocally regulate Th2/Th3 diff  erentiation. 
Therefore, suppression of SOCS3 expression in T cells may 
possibly be one of the ways to introduce tolerance for auto-
immune diseases or to ameliorate allergic diseases.
MATERIALS AND METHODS
Generation of T cell–specifi  c SOCS3-disrupted mice. SOCS-3 fl  ox/
fl  ox mice (22), and Lck-cre transgenic mice (41) have been described else-
where. Lck-cre transgenic mice (C57BL/6 background) were bred with 
SOCS3 fl  ox/fl  ox mice (129 × C57BL/6 background) to generate mice in 
which SOCS3 was deleted in a T cell–specifi  c manner. Genotypings were 
performed by PCR as described previously (22). Off  spring carrying both lck-
cre and fl  oxed SOCS3 genes (Lck-Cre:SOCS3 fl  ox/fl  ox; cKO) and the fl  oxed 
SOCS3 gene (SOCS3 fl  ox/fl  ox; WT) were used for intercrossing and further 
analyses. Littermate controls were used for all experiments. CD4+ T cells, 
splenic B cells, and DCs were isolated by MACS sorting as described previ-
ously (42). Mice were kept in specifi  c pathogen-free facilities in the Collab-
orative Station Animal Facility of Kyushu University. All experiments using 
these mice were approved by and performed according to the guidelines of 
the Animal Ethics Committee of Kyushu University, Fukuoka, Japan.
OVA/alum immunization and assay for airway hyperresponsiveness. 
Alhydrogel (alum; Al(OH)3gel) (LSL) was mixed with a predetermined quan-
tity of OVA grade V (Sigma-Aldrich) and incubated at room temperature for 
20 min. After centrifugation of the mixture at 14,000 g for 10 min, superna-
tants were used for immunization as described previously (24). Mice (8–12 
wk old) were immunized with 0.1 ml of OVA (10 μg) in PBS and absorbed 
to alum. Boosting inoculations were performed in the same fashion 2 wk 
later. For airway hyperresponsiveness (AHR) and eosinophil infi  ltration as-
say, mice received aerosol challenge containing either saline or 1% OVA for 
20 min/d on days 26–28 (18, 43). On day 30, 36 h after the last aerosol chal-
lenge, mice were ventilated and AHR to acetylcholine aerosol was measured. 
Serum levels of total and OVA-specifi  c Ig was analyzed by ELISA with rat 
anti–mouse Ig (Serotec Ltd.). Ab titers were determined by endpoint analysis. 
For cytokine assays, splenocytes from immunized mice on day 28 were cul-
tured ex vivo in the presence of OVA. Culture supernatants were harvested 
after 48 h and analyzed for IL-4, IFN-γ, TGF-β1, and IL-10 by ELISA.
L. major infection and cytokine assay. Infection of L. major was performed 
as described previously (44). Mice were infected s.c. in the right footpad 
  lesion with 107 stationary phase of L. major (MHOM/SU/73-5-ASKH). 
Footpad swelling was monitored weekly by a vernier caliper and compared 
with the thickness of the uninfected left footpad. 6 wk after infection, the 
footpad parasite burdens were quantifi  ed by homogenizing tissue in 3 ml of 
medium 199 supplemented with 10% FCS containing 2 mM glutamine, 10 
mM Hepes, and 100 μl/ml gentamicin. Aliquots were diluted serially across 
96-well plates and scored at 1 wk for the presence of motile promastigotes. 
4 wk after L. major infection, CD4+ T cells (5 × 105/200 μl/well) from the 
right popliteal LN were stimulated with or without L. major antigens (equiv-
alent to 5 × 105 promastigotes) in the presence of irradiated (30 Gy) spleno-
cytes for 70 h. Culture supernatants were collected and analyzed for IL-4, 
IFN-γ, TGF-β1, and IL-10 by ELISA. Total RNA was prepared from 
MACS-purifi  ed CD4+ T cells of popliteal LN 4 wk after L. major infection, 
and the expression level of G3PDH was fi  rst evaluated as an internal control. 
The pair of primers for TGF-β1 was forward, 5′-T  G  A  C  G  T  C  A  C  T  G  G  A  G  T-
T  G  T  A  C  G  G  -3′ and reverse, 5′-G  G  T  T  C  A  T  G  T  C  A  T  G  G  A  T  G  G  T  G  C  -3′. 
The expression levels of IFN-γ and IL-10 were assessed using appropriate 
pairs of primers described previously (44).
In vitro T cell diff  erentiation assay. For in vitro T cell diff  erentiation as-
says, CD4+ T cells (106 cells/ml) purifi  ed by MACS columns (Miltenyi Bio-
tec) from splenocytes after depletion of red blood cells were cultured in 
RPMI 1640 containing 10% FCS and stimulated with 1 μg/ml of plate-
bound anti-CD3ε mAb, 1 μg/ml anti-CD28 mAb, and 1 ng/ml mIL-2 
(PeproTech) supplemented with anti–IFN-γ and anti–IL-4 antibodies for 
Th0 diff  erentiation, 10 ng/ml mIL-12 (PeproTech) for Th1 diff  erentiation, 
10 ng/ml mIL-4 (PeproTech) for Th2 diff  erentiation, or 10 ng/ml mIL-4, 
10 ng/ml mIL-10 (PeproTech), and 10 ng/ml hTGF-β1 (PeproTech) for 
Th3 diff  erentiation (11). Cells were collected after 7 d and washed, and an 
equal numbers of viable cells (106 cells/ml) were restimulated with plate-
bound anti-CD3ε mAb and 1 μg/ml anti-CD28 mAb in the absence of any 
additional cytokines. Supernatants were collected 24 h later, and the produc-
tion of cytokines was measured in duplicate by ELISA (Genzyme). For mea-
surement of TGF-β1 production, secondary stimulation was done in a 
serum-free medium in which Nutridoma SP (Roche Diagnostic) was substi-
tuted for FCS. Supernatant was collected 72 h after secondary stimulation for 
TGF-β1 measurement using mTGF-β1 ELISA kit (Promega).
Construction of reporter plasmids. PCR was done to generate the 
TGF-β1 promoter plasmid by using mouse genomic DNA as a template. 
The nucleotide sequence of the mTGF-β1 promoter has been submitted to 
GenBankTM/EBI Data Bank under accession no. L42456.1. A 4.1-kb 
XhoI–EcoRI fragment corresponding to nucleotides from −3245 to +845 
relative to the determined transcriptional start site of TGF-β1 gene was sub-
cloned into a pGV-basic2 vector (TOYOINKI), pTGF4.1-luc. Reporter 
plasmids, including a series of deletion mutants of the TGF-β1 promoter, 
were generated by excision at restriction enzyme recognition sites as follows: 
−2977 (NcoI), −1755 (HindIII), −1072 (SmaI), −585 (NcoI). To con-
struct SBE-1mt, SBE-2mt, and SBE-1mt/2mt, point mutations were intro-
duced to the two STAT binding elements (SBE-1/SBE-2) by PCR using 
the KOD-plus polymerase (TOYOBO) and the sequences are as follows: 
SBE-1mt, 5′-G  C  A  G  A  C  G  C  T  G  G  G  A  C  T  G  A  -3′ and SBE-2mt, 5′-T  T  C  T  C-
T  G  A  C  C  G  G  G  A  C  C  A  T  T  T  T  -3′ (mutated sites are underlined). The sub-
cloned PCR products were sequenced to confi  rm that the products were the 
authentic promoter fragments.
Transfection and luciferase assay. HEK293 (105 cells) were seeded on 
six-well plates, cultured for 24 h, and transfected with various amounts of an 
expression vector of WT-STAT3-pCDNA3 or STAT3c-pRcCMV along 
with 0.2 μg of TGF-β1-pGVbasic2 and 0.1 μg of β-galactosidase (β-gal) 
plasmid by the calcium phosphate coprecipitation method. Some of them 
were stimulated with LIF (10 ng/ml) or TGF-β1 (10 ng/ml) for 8 h. Cells 
were harvested in 40 μl lysis buff  er. Luciferase assay was performed using a 
luciferase substrate kit (Promega) and luciferase activity was read in Packard 
luminometer. Luciferase activity was normalized by the internal control 
β-gal activity, and shown as the means ± SD of three to fi  ve experiments.
ChIP assay. ChIP assay was performed in 107 mouse T lymphocytes. Cells 
were fi  xed with 1% formaldehyde at 37°C for 10 min after IL-6 stimula-
tion as described previously (31). Cells were washed, suspended in SDS 
lysis buff  er, and sonicated for 30-s pulses four times using a sonicator (Bi-
oruptor; Cosmo Bio Co.). Samples were incubated with 5 μg anti-STAT3 
antibody (C-20; Santa Cruz Biotechnology, Inc.) overnight at 4°C. After 
adding salmon sperm DNA and protein A–Agarose Slurry (UBI), the im-
munoprecipitates were sequentially washed with low-salt buff  er, high-salt 
buff  er, LiCl buff  er and twice with TE buff  er. The DNA–protein complex 
was eluted into elution by heating at 65°C for 6 h. Proteins were digested 
by proteinase K and RNA was removed by addition of 10 μg of RNase A.
DNA was recovered by extraction with phenol and chloroform and ethanol 
precipitation and subjected to PCR analysis. To estimate the DNA   content 
in the soluble chromatin samples, DNA was similarly extracted from 
sonicated samples and used as a template for G3PDH gene amplifi  cation. 
Promoter-specifi   c primers were as follows; mTGF-β1, SBE-1 forward: 
5′-T  G  A  C  T  A  A  C  G  G  C  A  C  T  G  A  G  G  A  G  G  C  T  G  C  -3′, SBE-1 reverse: 5′-T  G  G-
A  A  A  C  A  G  G  T  C  T  A  T  C  T  T  C  T  A  C  C  T  A  -3′, which amplify 311-bp fragments 
fl  anking the STAT3 binding element. For negative control, 5′ franking 
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5′-G  T  G  C  C  T  C  C  T  T  G  T  A  T  C  C  G  C  T  A  A  A  G  C  T  C  T  C  -3′ and reverse: 5′-A  C-
T  A  C  T  A  A  A  G  C  C  G  G  T  G  A  C  C  A  A  C  C  A  A  A  G  -3′. The mouse c-fos primers for 
the positive control of STAT3-ChIP are forward: 5′-T  C  T  G  C  C  T  T  T  C  C  C-
G  C  C  T  C  C  C  C  -3′ and reverse: 5′-G  G  C  C  G  T  G  G  A  A  A  C  C  T  G  C  T  G  A  C  -3′.
Retroviral constructs and transduction to primary T cells. The 
STAT3c-IRES-GFP-pMX, dNSTAT3-IRES-GFP-pMX, and empty GFP-
pMX plasmids (a gift from T. Kitamura, Tokyo University, Tokyo, Japan) 
were transfected into a packaging cell line, Plat-E (33), using FuGENE6 
(Roche Diagnostic), and after incubation for 48 h, the culture supernatant 
were harvested. CD4+ enriched T cells were stimulated with 1 μg/ml anti-
CD3ε mAb and 1 μg/ml anti-CD28 mAb for 24 h and infected with the vi-
ruses by adding the viral containing supernatants in the presence of 0.6 
μg/ml polybrene (Sigma-Aldrich). The infected CD4+ T cells were ex-
panded in the medium supplemented with 100 U/ml rIL-2 for 4 d. GFP-
positive cells were collected by a cell sorter (EPICS ALTRA; Beckman 
Coulter) and restimulated with 1 μg/ml anti-CD3ε mAb and 1 μg/ml anti-
CD28 mAb or Th3-inducing condition for 72 h. Culture supernatants were 
harvested after 48 h to analyze TGF-β1 and IL-10 production by ELISA.
Online supplemental material. Fig. S1 shows tyrosine phosphorylation 
of cellular proteins (anti-pY blot) and ERK activation in CD4+ T cells from 
WT and cKO mice after TCR stimulation. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20052333/DC1.
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